Stock listing
NASDAQ:OBX Obsidian Therapeutics, Inc. Stock
Follow Obsidian Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:OBX
$12.00 USD -0.21 (-1.7%)
Close on Nov 20, 2026
- Day range
- $11.76 – $12.30 USDNov 20, 2026
- Volume
- 336,497 sharesNov 20, 2026
- Market cap
- $741.3M USDAt the close on Nov 20, 2026 · price × 61.77M shares outstanding
- Traded on an average day
- $7.86M USDMedian day 378,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OBX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.00 | -0.21 | -1.7% | $12.22 | $12.30 | $11.76 | 336,497 | |
| $12.21 | +0.14 | +1.2% | $12.00 | $13.25 | $11.73 | 681,209 | |
| $12.07 | -0.29 | -2.3% | $12.26 | $12.51 | $11.88 | 282,021 | |
| $12.36 | -0.20 | -1.6% | $12.50 | $12.71 | $11.85 | 727,802 | |
| $12.56 | +0.08 | +0.6% | $12.37 | $13.00 | $11.80 | 314,041 | |
| $12.48 | -0.40 | -3.1% | $12.99 | $13.04 | $12.00 | 328,740 | |
| $12.88 | -0.86 | -6.3% | $13.77 | $14.00 | $12.82 | 663,422 | |
| $13.74 | +0.03 | +0.2% | $13.39 | $14.03 | $12.74 | 743,997 | |
| $13.71 | -0.16 | -1.2% | $13.34 | $14.20 | $12.40 | 1,143,732 | |
| $13.87 | +4.27 | +44.5% | $10.41 | $14.77 | $9.71 | 2,091,400 | |
| $9.60 | -1.39 | -12.6% | $10.98 | $10.98 | $9.60 | 778,300 | |
| $10.99 | -2.24 | -16.9% | $13.55 | $13.75 | $10.60 | 544,000 | |
| $13.23 | -1.20 | -8.3% | $14.23 | $14.97 | $13.01 | 626,800 | |
| $14.43 | -0.36 | -2.4% | $14.62 | $14.92 | $13.48 | 526,000 | |
| $14.79 | +0.27 | +1.9% | $14.55 | $15.52 | $13.66 | 563,000 | |
| $14.52 | -0.07 | -0.5% | $14.67 | $15.87 | $14.30 | 248,200 | |
| $14.59 | +0.34 | +2.4% | $13.38 | $15.00 | $13.38 | 412,000 | |
| $14.25 | +0.39 | +2.8% | $13.72 | $14.31 | $13.20 | 397,700 | |
| $13.86 | -0.12 | -0.9% | $14.07 | $14.30 | $13.16 | 204,800 | |
| $13.98 | +0.04 | +0.3% | $13.83 | $14.17 | $13.43 | 279,800 | |
| $13.94 | +0.01 | +0.1% | $14.10 | $14.50 | $13.74 | 174,200 | |
| $13.93 | +0.68 | +5.1% | $13.34 | $14.60 | $13.34 | 332,800 | |
| $13.25 | +1.31 | +11.0% | $11.97 | $13.47 | $11.57 | 410,900 | |
| $11.94 | +0.17 | +1.4% | $11.75 | $12.00 | $11.52 | 106,400 | |
| $11.77 | -0.43 | -3.5% | $12.31 | $12.46 | $11.62 | 297,700 | |
| $12.20 | -0.02 | -0.2% | $12.31 | $12.67 | $12.06 | 240,300 | |
| $12.22 | +0.23 | +1.9% | $12.00 | $12.67 | $11.79 | 298,300 | |
| $11.99 | -0.80 | -6.3% | $12.96 | $13.18 | $11.86 | 377,300 | |
| $12.79 | -0.21 | -1.6% | $13.13 | $13.21 | $12.61 | 420,000 | |
| $13.00 | +0.76 | +6.2% | $12.25 | $13.95 | $12.25 | 532,200 | |
| $12.24 | -0.96 | -7.3% | $13.14 | $13.39 | $12.07 | 517,100 | |
| $13.20 | -0.02 | -0.2% | $13.02 | $13.88 | $12.80 | 359,000 | |
| $13.22 | -0.62 | -4.5% | $13.84 | $14.42 | $13.00 | 288,800 | |
| $13.84 | +0.25 | +1.8% | $13.45 | $14.26 | $13.09 | 199,200 | |
| $13.59 | +0.27 | +2.0% | $13.07 | $13.90 | $13.07 | 229,000 | |
| $13.32 | -0.41 | -3.0% | $13.86 | $14.68 | $13.16 | 299,800 | |
| $13.73 | -0.85 | -5.8% | $14.58 | $14.70 | $13.11 | 351,600 | |
| $14.58 | +1.21 | +9.1% | $13.28 | $15.38 | $12.80 | 378,600 | |
| $13.37 | +0.51 | +4.0% | $12.91 | $13.73 | $12.33 | 913,000 | |
| $12.86 | -0.55 | -4.1% | $13.54 | $13.70 | $12.16 | 454,500 | |
| $13.41 | -1.85 | -12.1% | $15.27 | $15.66 | $13.20 | 426,600 | |
| $15.26 | -1.74 | -10.2% | $17.10 | $17.10 | $15.25 | 582,600 | |
| $17.00 | -0.33 | -1.9% | $17.44 | $17.97 | $16.71 | 1,151,600 | |
| $17.33 | -0.42 | -2.4% | $18.08 | $18.21 | $17.14 | 1,104,800 | |
| $17.75 | +0.25 | +1.4% | $17.61 | $18.16 | $17.36 | 3,974,300 | |
| $17.50 | +0.35 | +2.0% | $17.16 | $18.19 | $17.16 | 829,600 | |
| $17.15 | +0.15 | +0.9% | $17.29 | $18.10 | $16.91 | 1,167,000 | |
| $17.00 | -1.10 | -6.1% | $18.17 | $18.75 | $17.00 | 472,300 | |
| $18.10 | +0.30 | +1.7% | $18.39 | $19.00 | $17.84 | 455,500 | |
| $17.80 | +0.64 | +3.7% | $17.23 | $18.49 | $17.17 | 392,800 | |
| $17.16 | -1.52 | -8.1% | $18.65 | $19.55 | $17.00 | 454,200 | |
| $18.68 | -0.05 | -0.3% | $18.16 | $19.97 | $18.16 | 332,200 | |
| $18.73 | +1.91 | +11.4% | $16.98 | $19.87 | $16.98 | 599,400 | |
| $16.82 | -0.27 | -1.6% | $17.26 | $19.00 | $16.57 | 140,100 | |
| $17.09 | +0.09 | +0.5% | $16.85 | $18.06 | $16.15 | 136,200 | |
| $17.00 | -0.04 | -0.2% | $17.35 | $18.02 | $16.25 | 126,300 | |
| $17.04 | -0.47 | -2.7% | $17.18 | $18.10 | $16.27 | 79,300 | |
| $17.51 | +1.21 | +7.4% | $16.55 | $17.99 | $15.53 | 142,500 | |
| $16.30 | -0.74 | -4.3% | $16.58 | $18.11 | $15.85 | 260,500 | |
| $17.04 | -1.36 | -7.4% | $17.80 | $18.72 | $16.80 | 65,100 | |
| $18.40 | -0.60 | -3.2% | $18.32 | $19.20 | $17.79 | 118,400 | |
| $19.00 | +0.30 | +1.6% | $19.29 | $19.44 | $18.50 | 155,712 | |
| $18.70 | -1.20 | -6.0% | $20.39 | $21.98 | $17.80 | 133,102 | |
| $19.90 | -0.29 | -1.4% | $20.47 | $21.33 | $18.44 | 1,449,300 | |
| $20.19 | +0.19 | +1.0% | $20.20 | $21.03 | $19.70 | 74,400 |
- Ticker
- NASDAQ:OBX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 27 slides
Latest news
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Nov 12, 2026
Closed $12.56 (+0.6%) on Nov 13, 2026
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
Nov 6, 2026
Closed $13.87 (+44.5%) on Nov 6, 2026
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Oct 2, 2026
Closed $13.59 (+2.0%) on Oct 2, 2026
Obsidian Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 1 deck · latest August 2026
Valuation
P/E 13.0× against a median of 7.5×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $530.4M USD
- P/E
- 13.0×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$600.0M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Inventiva SA · EURONEXT:IVA | US$760.9M | US$577.3M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Aimed Bio Inc. · KRX:0009K0 | US$726.5M | US$657.3M | 25.2× | 13.2× | 34.0× | 4.8× | 57.8% | 0.0× | n/a |
| Aura Biosciences, Inc. · NASDAQ:AURA | US$715.0M | US$433.9M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.07 |
| Median of the others | US$762.9M | US$628.6M | 7.5× | 2.4× | 8.3× | 3.0× | 28.4% | 0.0× | 1.07 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.85 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Madan Jagasia | Chief Executive Officer |
| Caroline Code | VP Corporate Development and Investor Relations |
| Nicole Hsu | VP, Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Maria Fardis | Chair of the Board of Directors |
| Heidi Hagen | Board Member |
| Madan Jagasia | Chief Executive Officer |
| Matthew Norkunas | Board Member |
| Peter Barrett | Board Member |
| Rob Ross | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +0.6% |
| Q2 2026 | Aug 12, 2026 | −42.5% |
| Q1 2026 | May 11, 2026 | |
| Q4 2025 | Mar 26, 2026 | |
| Q3 2025 | Nov 28, 2025 | |
| Q2 2025 | Aug 29, 2025 | |
| Q1 2025 | May 30, 2025 | |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | |
| Quarter to Jun 30, 2024 | Aug 14, 2024 | |
| Quarter to Mar 31, 2024 | May 13, 2024 |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2023 | Mar 28, 2024 | |
| Q3 2023 | Nov 14, 2023 | |
| Q2 2023 | Aug 14, 2023 | |
| Q1 2023 | May 11, 2023 | |
| Q4 2022 | Mar 8, 2023 | |
| Quarter to Sep 30, 2022 | Nov 9, 2022 | |
| Quarter to Jun 30, 2022 | Aug 9, 2022 | |
| Quarter to Mar 31, 2022 | May 16, 2022 | |
| Quarter to Dec 31, 2021 | Mar 10, 2022 | |
| Quarter to Sep 30, 2021 | Nov 10, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 27 slides | August 2026 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 86.1M | 73.2M |
| Selling, general and administrative | 19.6M | 18.1M |
| Operating income | -105.7M | -91.3M |
| Depreciation and amortization | 1.48M | 1.53M |
| EBITDA | -104.2M | -89.7M |
| Income before tax | -100.6M | -83.1M |
| Net income | -100.6M | -83.1M |
| Earnings per share, basic | -1.63 | -1.35 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 40.4M | 49.8M |
| Short-term investments | 40.1M | 118.5M |
| Current assets | 81.5M | 172.8M |
| Total assets | 88.6M | 183.7M |
| Accounts payable | 12.0K | 1.82M |
| Current liabilities | 15.4M | 16.1M |
| Total debt | 4.28M | |
| Total liabilities | 354.6M | 358.1M |
| Shareholders' equity | -266.0M | -174.4M |
| Shares outstanding | 61.6M | 61.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Cash from operations | -90.4M | -75.0M | |||
| Capital spending | -73.0K | -779.0K | 0 | 0 | 0 |
| Free cash flow | -90.5M | -75.8M | |||
| Cash from investing | 81.0M | ||||
| Cash from financing | 20.0K | 162.5M | |||
| Change in cash | -9.36M | 33.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 13, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 5, 2026 | Big-stake notice | SEC |
All 44 filings
Cap table
Built by 6ix from Obsidian Therapeutics, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 61,774,046
- Fully diluted
- 61,774,046
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 61,774,046 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 61,774,046 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Barrett Other companies: Synlogic Inc (Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022); Larimar Therapeutics, Inc. (Director · May 10, 2022 – May 10, 2022 · Past) | Director · Since at least Aug 3, 2026 |
| Heidi Hagen Other companies: Vericel Corporation (Director · Since at least Aug 23, 2013); Alaunos Therapeutics, Inc. (Director · Jun 13, 2019 – Sep 2, 2021 · Past) | Director · Since at least Aug 3, 2026 |
| Caroline Code Other companies: Galera Therapeutics, Inc. (VP Corporate Development & Investor Relations · Since at least Apr 14, 2026) | VP Corporate Development and Investor Relations · Since at least Aug 5, 2026 |
| Maria Fardis Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025) | Director · Since at least Aug 3, 2026 |
| Matthew Norkunas Other companies: Generation Bio Co (CHIEF FINANCIAL OFFICER · Jan 22, 2021 – Jan 10, 2025 · Past) | Director · Since at least Aug 3, 2026 |
| Robert Ross Other companies: Xilio Therapeutics, Inc. (Board Member · Since at least Jun 14, 2024) | Director · Since at least Aug 3, 2026 |
| Madan Jagasia | Chief Executive Officer, Director · Since at least Aug 3, 2026 |
| Nicole Hsu | VP, Regulatory Affairs · Since at least Nov 5, 2026 |
| Parameswaran Hari | Chief Medical Officer · Since at least Aug 3, 2026 |
Log in to ask 6ix AI your own questions about Obsidian Therapeutics, Inc.